AR003475A1 - Nuevos peptidos opiaceos, composiciones farmaceuticas que los contienen, el uso de los mismos en la preparacion de formulaciones y un metodo para su preparacion. - Google Patents
Nuevos peptidos opiaceos, composiciones farmaceuticas que los contienen, el uso de los mismos en la preparacion de formulaciones y un metodo para su preparacion.Info
- Publication number
- AR003475A1 AR003475A1 ARP960103900A AR10390096A AR003475A1 AR 003475 A1 AR003475 A1 AR 003475A1 AR P960103900 A ARP960103900 A AR P960103900A AR 10390096 A AR10390096 A AR 10390096A AR 003475 A1 AR003475 A1 AR 003475A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptides
- preparation
- new
- phe
- formulations
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- LSNDLIKCFHLFKO-JTQLQIEISA-N (2s)-2-azaniumyl-3-(4-hydroxy-2,6-dimethylphenyl)propanoate Chemical group CC1=CC(O)=CC(C)=C1C[C@H](N)C(O)=O LSNDLIKCFHLFKO-JTQLQIEISA-N 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 abstract 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical group OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 abstract 1
- 102000001490 Opioid Peptides Human genes 0.000 abstract 1
- 108010093625 Opioid Peptides Proteins 0.000 abstract 1
- 102000003840 Opioid Receptors Human genes 0.000 abstract 1
- 108090000137 Opioid Receptors Proteins 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000003399 opiate peptide Substances 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Esta invención se refiere a nuevos péptidos opiáceos (I), y sales, derivados y sus análogos en los que, R1 es Tyr ó 2,6-dimetiltirosina, o unanálogo o su derivado;R2 es D-Ala ó D-Arg;R3 es Phe(p-F); R4 es Phe ó Phe(p-F); X es H o C1-6-alquil o; y Y y Z son independientemente H, aralquilo;ó -C1-6alquilo;tratamiento del dolor así como también al método para su preparación y a las composiciones farmacéuticamente aceptables que comprenden a estospéptidos.La invención también serefiere al u so de estos compuestos en la preparación de las formulaciones efectivas para el tratamiento del dolor. Lospéptidos de esta invención tienen un grado alto de selectividad para el receptor opiáceo (mu).Asimismo péptidos dela presente inv ención sonparticularmente analgésicos que actúan substancialmente sobre los receptores periféricos opiáceos my. Debido a que estos péptidos actúan periféricamente,evitan substancialmente los efectos colaterales normalmenteasociados con la acci ón analgésica central.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9502877A SE9502877D0 (sv) | 1995-08-18 | 1995-08-18 | Novel opioid peptides |
| SE9503924A SE9503924D0 (sv) | 1995-08-18 | 1995-11-07 | Novel opioid peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR003475A1 true AR003475A1 (es) | 1998-08-05 |
Family
ID=26662362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960103900A AR003475A1 (es) | 1995-08-18 | 1996-08-06 | Nuevos peptidos opiaceos, composiciones farmaceuticas que los contienen, el uso de los mismos en la preparacion de formulaciones y un metodo para su preparacion. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6337319B1 (es) |
| EP (1) | EP0845003B1 (es) |
| JP (1) | JPH11512086A (es) |
| KR (1) | KR19990037677A (es) |
| CN (1) | CN1200127A (es) |
| AR (1) | AR003475A1 (es) |
| AT (1) | ATE210148T1 (es) |
| AU (1) | AU711862B2 (es) |
| BR (1) | BR9610248A (es) |
| CA (1) | CA2229797A1 (es) |
| CZ (1) | CZ287299B6 (es) |
| DE (1) | DE69617699T2 (es) |
| DK (1) | DK0845003T3 (es) |
| EE (1) | EE9800048A (es) |
| ES (1) | ES2171224T3 (es) |
| HU (1) | HUP9901209A3 (es) |
| IL (1) | IL123258A (es) |
| IS (1) | IS4664A (es) |
| NO (1) | NO980592D0 (es) |
| NZ (1) | NZ315809A (es) |
| PL (1) | PL325113A1 (es) |
| RU (1) | RU2165432C2 (es) |
| SE (1) | SE9503924D0 (es) |
| SK (1) | SK282469B6 (es) |
| TR (1) | TR199800258T1 (es) |
| TW (1) | TW424095B (es) |
| WO (1) | WO1997007130A1 (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030032774A1 (en) * | 1994-02-21 | 2003-02-13 | Astrazeneca Ab | Novel opioid peptides for the treatment of pain |
| US5885958A (en) * | 1997-03-25 | 1999-03-23 | Administrators Of The Tulane Educational Fund | Mu-opiate receptor peptides |
| SE9701718D0 (sv) * | 1997-05-07 | 1997-05-07 | Astra Ab | Analgesic peptidomimetic compounds |
| SE9800865D0 (sv) * | 1998-03-16 | 1998-03-16 | Astra Ab | New Process |
| WO2001013938A1 (fr) * | 1999-08-25 | 2001-03-01 | Daiichi Fine Chemical Co., Ltd. | Composition therapeutique pouvant etre administree par voie percutanee ou par les muqueuses |
| AU1623801A (en) * | 1999-11-19 | 2001-05-30 | Palatin Technologies, Inc. | Opioid metallopeptide compositions and methods |
| US7498297B2 (en) | 2000-07-18 | 2009-03-03 | Cornell Research Foundation | Medicinal uses of mu-opioid receptor agonists |
| JP2002069059A (ja) * | 2000-08-28 | 2002-03-08 | Teikoku Seiyaku Co Ltd | ピラジノン環を含む新規なオピオイドペプチド誘導体 |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| CA2580694A1 (en) * | 2004-09-23 | 2006-03-30 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| DE102005005449A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| WO2006132925A2 (en) | 2005-06-01 | 2006-12-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy |
| EP1782819A1 (en) | 2005-11-03 | 2007-05-09 | Cognis IP Management GmbH | Oligopeptides and their use |
| US8906859B2 (en) | 2006-11-10 | 2014-12-09 | Cera Therapeutics, Inc. | Uses of kappa opioid synthetic peptide amides |
| US7713937B2 (en) | 2006-11-10 | 2010-05-11 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
| US8236766B2 (en) | 2006-11-10 | 2012-08-07 | Cara Therapeutics, Inc. | Uses of synthetic peptide amides |
| JP5244810B2 (ja) | 2006-11-10 | 2013-07-24 | カラ セラピューティクス インコーポレイテッド | 合成ペプチドアミド |
| US7842662B2 (en) | 2006-11-10 | 2010-11-30 | Cara Therapeutics, Inc. | Synthetic peptide amide dimers |
| AU2009207796B2 (en) | 2008-01-25 | 2014-03-27 | Grunenthal Gmbh | Pharmaceutical dosage form |
| AU2009243681B2 (en) * | 2008-05-09 | 2013-12-19 | Grunenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
| MX2012000317A (es) | 2009-07-22 | 2012-02-08 | Gruenenthal Gmbh | Forma de dosificacion de liberacion controlada extruida por fusion en caliente. |
| AR077420A1 (es) | 2009-07-22 | 2011-08-24 | Gruenenthal Gmbh | Forma de dosificacion resistente a la manipulacion para opiaceos sensibles a la oxidacion |
| US9579285B2 (en) * | 2010-02-03 | 2017-02-28 | Gruenenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of an extruder |
| US20160176930A1 (en) | 2010-07-09 | 2016-06-23 | The Administrators Of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
| NZ607392A (en) | 2010-09-02 | 2015-03-27 | Gruenenthal Chemie | Tamper resistant dosage form comprising inorganic salt |
| JP5933553B2 (ja) | 2010-09-02 | 2016-06-15 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | アニオン性ポリマーを含む不正使用抵抗性剤形 |
| SI2736495T1 (sl) | 2011-07-29 | 2017-12-29 | Gruenenthal Gmbh | Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila |
| AR087359A1 (es) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco |
| EP2819656A1 (en) | 2012-02-28 | 2015-01-07 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| TR201815502T4 (tr) | 2012-04-18 | 2018-11-21 | Gruenenthal Gmbh | Kurcalama veya dirençli ve doz boşalımına dirençli farmasötik dozaj formu. |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| CN102964279B (zh) * | 2012-12-12 | 2014-05-07 | 中国药科大学 | 一类具有外周镇痛作用的κ阿片受体激动剂 |
| CA2913209A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper resistant dosage form with bimodal release profile |
| US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
| CN105682643B (zh) | 2013-07-12 | 2019-12-13 | 格吕伦塔尔有限公司 | 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型 |
| CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
| AU2015261060A1 (en) | 2014-05-12 | 2016-11-03 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising Tapentadol |
| CN106456550A (zh) | 2014-05-26 | 2017-02-22 | 格吕伦塔尔有限公司 | 避免乙醇剂量倾泻的多颗粒 |
| HK1246173A1 (zh) | 2015-04-24 | 2018-09-07 | Grünenthal GmbH | 具有立即释放和对溶剂萃取的抗性的抗篡改剂型 |
| EP3346991A1 (en) | 2015-09-10 | 2018-07-18 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0350221B1 (en) * | 1988-06-30 | 1996-04-17 | Astra Aktiebolag | Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same |
| AU672077B2 (en) * | 1992-11-12 | 1996-09-19 | Biomeasure, Inc. | Opioid peptides |
| SE9300012D0 (sv) * | 1993-01-05 | 1993-01-05 | Astra Ab | New peptides |
| IS4261A (is) * | 1994-02-21 | 1995-08-22 | Astra Aktiebolag | Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra |
-
1995
- 1995-11-07 SE SE9503924A patent/SE9503924D0/xx unknown
-
1996
- 1996-08-06 AR ARP960103900A patent/AR003475A1/es active IP Right Grant
- 1996-08-14 TR TR1998/00258T patent/TR199800258T1/xx unknown
- 1996-08-14 SK SK203-98A patent/SK282469B6/sk unknown
- 1996-08-14 JP JP9509209A patent/JPH11512086A/ja active Pending
- 1996-08-14 AT AT96927978T patent/ATE210148T1/de not_active IP Right Cessation
- 1996-08-14 DE DE69617699T patent/DE69617699T2/de not_active Expired - Fee Related
- 1996-08-14 CA CA002229797A patent/CA2229797A1/en not_active Abandoned
- 1996-08-14 EE EE9800048A patent/EE9800048A/xx unknown
- 1996-08-14 ES ES96927978T patent/ES2171224T3/es not_active Expired - Lifetime
- 1996-08-14 CN CN96197625A patent/CN1200127A/zh active Pending
- 1996-08-14 CZ CZ1998401A patent/CZ287299B6/cs not_active IP Right Cessation
- 1996-08-14 PL PL96325113A patent/PL325113A1/xx unknown
- 1996-08-14 RU RU98104253/04A patent/RU2165432C2/ru active
- 1996-08-14 BR BR9610248A patent/BR9610248A/pt unknown
- 1996-08-14 HU HU9901209A patent/HUP9901209A3/hu unknown
- 1996-08-14 IL IL12325896A patent/IL123258A/xx not_active IP Right Cessation
- 1996-08-14 AU AU67600/96A patent/AU711862B2/en not_active Ceased
- 1996-08-14 EP EP96927978A patent/EP0845003B1/en not_active Expired - Lifetime
- 1996-08-14 US US08/718,585 patent/US6337319B1/en not_active Expired - Fee Related
- 1996-08-14 DK DK96927978T patent/DK0845003T3/da active
- 1996-08-14 NZ NZ315809A patent/NZ315809A/xx unknown
- 1996-08-14 KR KR1019980701156A patent/KR19990037677A/ko not_active Ceased
- 1996-08-14 WO PCT/SE1996/001011 patent/WO1997007130A1/en not_active Ceased
- 1996-08-15 TW TW085109918A patent/TW424095B/zh not_active IP Right Cessation
-
1998
- 1998-02-04 IS IS4664A patent/IS4664A/is unknown
- 1998-02-11 NO NO980592A patent/NO980592D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL123258A (en) | 2003-03-12 |
| US6337319B1 (en) | 2002-01-08 |
| EP0845003B1 (en) | 2001-12-05 |
| AU711862B2 (en) | 1999-10-21 |
| DE69617699T2 (de) | 2003-08-07 |
| CN1200127A (zh) | 1998-11-25 |
| SE9503924D0 (sv) | 1995-11-07 |
| EP0845003A1 (en) | 1998-06-03 |
| KR19990037677A (ko) | 1999-05-25 |
| AU6760096A (en) | 1997-03-12 |
| NZ315809A (en) | 1999-05-28 |
| IS4664A (is) | 1998-02-04 |
| RU2165432C2 (ru) | 2001-04-20 |
| HUP9901209A2 (hu) | 1999-08-30 |
| DE69617699D1 (de) | 2002-01-17 |
| BR9610248A (pt) | 1999-07-06 |
| WO1997007130A1 (en) | 1997-02-27 |
| IL123258A0 (en) | 1998-09-24 |
| TR199800258T1 (xx) | 1998-05-21 |
| TW424095B (en) | 2001-03-01 |
| ATE210148T1 (de) | 2001-12-15 |
| CZ287299B6 (en) | 2000-10-11 |
| EE9800048A (et) | 1998-08-17 |
| NO980592L (no) | 1998-02-11 |
| SK282469B6 (sk) | 2002-02-05 |
| DK0845003T3 (da) | 2002-07-15 |
| ES2171224T3 (es) | 2002-09-01 |
| HUP9901209A3 (en) | 2000-12-28 |
| NO980592D0 (no) | 1998-02-11 |
| PL325113A1 (en) | 1998-07-06 |
| SK20398A3 (en) | 1998-12-02 |
| CZ40198A3 (cs) | 1998-08-12 |
| CA2229797A1 (en) | 1997-02-27 |
| JPH11512086A (ja) | 1999-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR003475A1 (es) | Nuevos peptidos opiaceos, composiciones farmaceuticas que los contienen, el uso de los mismos en la preparacion de formulaciones y un metodo para su preparacion. | |
| ES2163444T3 (es) | Composiciones y metodos para la administracion oral de farmacos. | |
| ES2166166T3 (es) | Analogos de peptido lh-rh, sus usos y composiciones farmaceuticas que los contienen. | |
| ES2128791T3 (es) | Derivados espirocetales, composiciones que los contienen y su uso como agentes terapeuticos. | |
| GT199700095A (es) | Derivados 6,5-heterobiciclicos sustituidos. | |
| PH16791A (en) | Angiotensin-ii analogues with antagonizing effects,containing an ester group in position 8 | |
| ES2167592T3 (es) | Preparaciones medicamentosas que contienen un enantiomero de bromuro de ipratropio con duracion de la accion prolongada. | |
| ES2168487T3 (es) | Derivados de n-heteroaril-piridinasulfonamida y su uso como antagonistas de la endotelina. | |
| ES2159738T3 (es) | Derivados de benzamida y su uso como antagonistas de vasopresina. | |
| ECSP941122A (es) | Derivados de 5-arilindoles | |
| FI980822A7 (fi) | Farmaseuttinen koostumus vaikuttavan aineen iho- tai limakalvopintaan tai iho- tai limakalvopinnan läpi | |
| CO4290424A1 (es) | Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina | |
| MX9301929A (es) | Derivados de pirimidina y procedimientos para su preparacion. | |
| BR0012082A (pt) | Formulação farmacêutica para administração compreendendo morfina e seu uso | |
| SE9604341D0 (sv) | Hepta-peptide oxytocin analogue | |
| AR003966A1 (es) | Un derivado de difenilmetilenpiperidina, composición farmacéutica que lo contiene, metodo de preparación de dicho derivado y uso de este ultimo para preparar un medicamento | |
| MX9301197A (es) | Derivados de indol. | |
| GT199700037A (es) | Composiciones farmaceuticas para el tratamiento de la rinitis | |
| ES2179996T3 (es) | Cefalosporinas de vinil-pirrolidinona con sustituyentes basicos. | |
| MX9400255A (es) | Analogos de peptidos opioides, metodo para su preparacion y composiciones farmaceuticas que los incluyen. | |
| AR005102A1 (es) | Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento. | |
| ES2093782T3 (es) | Piridazindionas y su uso en el tratamiento de trastornos neurologicos. | |
| DE69824313D1 (de) | Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen | |
| ES2189956T3 (es) | Derivados de quinolina, procedimientos para su preparacion y su uso como medicamentos. | |
| EP0553113A4 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |